Cargando…
Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
Mycobacteria harbor two main degradative proteolytic machineries, the caseinolytic protease ClpP1P2 and a proteasome. We recently showed that Bortezomib inhibits ClpP1P2 and exhibits whole cell activity against Mycobacterium tuberculosis. Bortezomib, a dipeptide with a boronic acid warhead, is a hum...
Autores principales: | Moreira, Wilfried, Santhanakrishnan, Sridhar, Dymock, Brian W., Dick, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406460/ https://www.ncbi.nlm.nih.gov/pubmed/28496439 http://dx.doi.org/10.3389/fmicb.2017.00746 |
Ejemplares similares
-
Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome
por: Moreira, Wilfried, et al.
Publicado: (2017) -
Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease
por: Yamada, Yoshiyuki, et al.
Publicado: (2017) -
Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria
por: Moreira, Wilfried, et al.
Publicado: (2015) -
Synthesis and Biochemical Evaluation of Warhead-Decorated Psoralens as (Immuno)Proteasome Inhibitors
por: Schiffrer, Eva Shannon, et al.
Publicado: (2021) -
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)